Submissions for variant NM_000256.3(MYBPC3):c.1828G>C (p.Asp610His)

gnomAD frequency: 0.00003  dbSNP: rs371564200

Total submissions: 11

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000035443	SCV000059091	uncertain significance	not specified	2018-03-07	criteria provided, single submitter	clinical testing	The p.Asp610His variant in MYBPC3 has been detected in 8 individuals with HCM (O livotto 2008, Millat 2010, Brito 2012, Rafael 2017 and LMM unpublished data) and one child who died from sudden infant death syndrome (SIDS; Brion 2012). Two of these individuals carried additional pathogenic variants and one individual was homozygous for the p.Asp610His variant (Rafael 2017, LMM data). In one family, this variant segregated with disease in 2 affected relatives, but was not presen t in an additional affected relative, raising the possibility that it may not be disease causing. The variant has also been identified in multiple older individ uals without disease. This variant has also been reported in ClinVar (Variation ID: 42576). This variant has also been identified in 6/113666 European chromosom es by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs371564200). Computational prediction tools suggest that the p.Asp610His variant may impact the protein, though this information is not predictive enoug h to determine pathogenicity. In summary, the clinical significance of the p.Asp 610His variant is uncertain. ACMG/AMP Criteria applied: PP3; PS4_Supporting; BP2 .
Ambry Genetics	RCV002310644	SCV000262974	uncertain significance	Cardiovascular phenotype	2023-08-04	criteria provided, single submitter	clinical testing	The p.D610H variant (also known as c.1828G>C), located in coding exon 19 of the MYBPC3 gene, results from a G to C substitution at nucleotide position 1828. The aspartic acid at codon 610 is replaced by histidine, an amino acid with similar properties. This alteration has been reported in multiple individuals with hypertrophic cardiomyopathy (HCM), but several of the probands were also heterozygous for pathogenic variants in other HCM-associated genes (Millat G et al. Eur J Med Genet 2010 Sep-Oct;53:261-7; Olivotto I et al. J. Am. Coll. Cardiol., 2011 Aug;58:839-48; Calore C et al. J. Med. Genet., 2015 May;52:338-47; Galati G et al. Circ Heart Fail, 2016 Sep;9; Rafael JF et al. Arq. Bras. Cardiol., 2017 Apr;108:354-360; Maurizi N et al. JAMA Cardiol, 2018 Jun;3:520-525). This alteration was also reported in cases of sudden infant death syndrome; however, limited clinical information was provided (Brion M et al. Forensic Sci. Int., 2012 Jun;219:278-81; Neubauer J et al. Eur. J. Hum. Genet., 2017 04;25:404-409). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Invitae	RCV000477331	SCV000546418	pathogenic	Hypertrophic cardiomyopathy	2024-01-13	criteria provided, single submitter	clinical testing	This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 610 of the MYBPC3 protein (p.Asp610His). This variant is present in population databases (rs371564200, gnomAD 0.008%). This missense change has been observed in individuals with hypertrophic cardiomyopathy, sudden infant death syndrome, and/or ventricular fibrillation (PMID: 8533079, 20624503, 22361390, 25740977, 28074886, 28356264, 29032884). ClinVar contains an entry for this variant (Variation ID: 42576). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant disrupts the p.Asp610 amino acid residue in MYBPC3. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 22857948, 33782553, 34097875; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
GeneDx	RCV000482228	SCV000565276	uncertain significance	not provided	2021-07-08	criteria provided, single submitter	clinical testing	In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Reported in ClinVar (ClinVar Variant ID#42576; Landrum et al., 2016); This variant is associated with the following publications: (PMID: 20624503, 20800588, 22361390, 27532257, 28074886, 28538763, 22958901, 27618852, 27535533, 28356264, 18533079, 21835320, 26582918, 29032884, 33782553, 32746448)
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute	RCV000622855	SCV000740355	uncertain significance	Primary familial hypertrophic cardiomyopathy	2016-07-26	criteria provided, single submitter	clinical testing
Illumina Laboratory Services, Illumina	RCV001106184	SCV001263223	uncertain significance	Left ventricular noncompaction 10	2017-04-27	criteria provided, single submitter	clinical testing	This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Illumina Laboratory Services, Illumina	RCV001106185	SCV001263224	uncertain significance	Hypertrophic cardiomyopathy 4	2017-04-27	criteria provided, single submitter	clinical testing	This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Color Diagnostics, LLC DBA Color Health	RCV001188105	SCV001355077	uncertain significance	Cardiomyopathy	2022-12-20	criteria provided, single submitter	clinical testing	This missense variant replaces aspartic acid with histidine at codon 610 of the MYBPC3 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 18533079, 20624503, 28356264, 28538763, 32531501, 33782553, 33495597). One of these individuals was compound heterozygous with a known pathogenic mutation in the same gene (PMID: 28538763). While this individual was reported to show severe phenotype, all other carriers of either of the two variants showed no clinical signs of hypertrophic cardiomyopathy. This variant has also been reported in an individual affected with dilated cardiomyopathy (PMID: 31983221) and in two individuals affected with sudden infant death syndrome (PMID: 22361390, 28074886). This variant has been identified in 8/253926 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Institute of Human Genetics, University of Leipzig Medical Center	RCV001106184	SCV001934563	likely pathogenic	Left ventricular noncompaction 10	2020-10-05	criteria provided, single submitter	clinical testing
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario	RCV001188105	SCV002042146	uncertain significance	Cardiomyopathy	2021-05-18	criteria provided, single submitter	clinical testing
AiLife Diagnostics, AiLife Diagnostics	RCV000482228	SCV002502007	likely pathogenic	not provided	2022-01-05	criteria provided, single submitter	clinical testing